These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 34649345)

  • 21. A neonatal mouse model of coxsackievirus A10 infection for anti-viral evaluation.
    Li S; Zhao H; Yang L; Hou W; Xu L; Wu Y; Wang W; Chen C; Wan J; Ye X; Liang Z; Mao Q; Cheng T; Xia N
    Antiviral Res; 2017 Aug; 144():247-255. PubMed ID: 28625478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection.
    Cai Y; Liu Q; Huang X; Li D; Ku Z; Zhang Y; Huang Z
    Vaccine; 2013 Apr; 31(18):2215-21. PubMed ID: 23499596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poorly neutralizing polyclonal antibody in vitro against coxsackievirus A16 circulating strains can prevent a lethal challenge in vivo.
    Yao X; Mao Q; Li Y; Hao C; Bian L; Chen P; Gao F; Wu X; Lu W; Gao Q; Li X; Liang Z
    Hum Vaccin Immunother; 2018 May; 14(5):1275-1282. PubMed ID: 29337652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.
    Liu CC; Guo MS; Wu SR; Lin HY; Yang YT; Liu WC; Chow YH; Shieh DB; Wang JR; Chong P
    Antiviral Res; 2016 May; 129():58-66. PubMed ID: 26899790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.
    Sun S; Jiang L; Liang Z; Mao Q; Su W; Zhang H; Li X; Jin J; Xu L; Zhao D; Fan P; An D; Yang P; Lu J; Lv X; Sun B; Xu F; Kong W; Jiang C
    Hum Vaccin Immunother; 2014; 10(10):2885-95. PubMed ID: 25483672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Production of EV71 vaccine candidates.
    Chong P; Hsieh SY; Liu CC; Chou AH; Chang JY; Wu SC; Liu SJ; Chow YH; Su IJ; Klein M
    Hum Vaccin Immunother; 2012 Dec; 8(12):1775-83. PubMed ID: 22992566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease.
    Fang CY; Liu CC
    Expert Rev Vaccines; 2018 Sep; 17(9):819-831. PubMed ID: 30095317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humoral and cellular immunogenicity and efficacy of a coxsackievirus A10 vaccine in mice.
    An HH; Li M; Liu RL; Wu J; Meng SL; Guo J; Wang ZJ; Qian SS; Shen S
    Emerg Microbes Infect; 2023 Dec; 12(1):e2147022. PubMed ID: 36373411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study of integrated protective immunity induced in rhesus macaques by the intradermal administration of a bivalent EV71-CA16 inactivated vaccine.
    Fan S; Liao Y; Jiang G; Jiang L; Wang L; Xu X; Feng M; Yang E; Zhang Y; Cui W; Li Q
    Vaccine; 2020 Feb; 38(8):2034-2044. PubMed ID: 31982260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice.
    Caine EA; Fuchs J; Das SC; Partidos CD; Osorio JE
    Viruses; 2015 Nov; 7(11):5919-32. PubMed ID: 26593938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of an efficient neutralization assay for Coxsackievirus A10.
    Liu D; Xu L; Zhu R; Yin Z; Lin Y; Hou W; Li S; He S; Cheng T; Xia N
    Appl Microbiol Biotechnol; 2019 Feb; 103(4):1931-1938. PubMed ID: 30617817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.
    Cai Y; Ku Z; Liu Q; Leng Q; Huang Z
    Vaccine; 2014 May; 32(21):2406-12. PubMed ID: 24657161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and structural characterization of a therapeutic antibody against coxsackievirus A10.
    Zhu R; Xu L; Zheng Q; Cui Y; Li S; He M; Yin Z; Liu D; Li S; Li Z; Chen Z; Yu H; Que Y; Liu C; Kong Z; Zhang J; Baker TS; Yan X; Hong Zhou Z; Cheng T; Xia N
    Sci Adv; 2018 Sep; 4(9):eaat7459. PubMed ID: 30255146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model.
    Hankaniemi MM; Laitinen OH; Stone VM; Sioofy-Khojine A; Määttä JAE; Larsson PG; Marjomäki V; Hyöty H; Flodström-Tullberg M; Hytönen VP
    Vaccine; 2017 Jun; 35(30):3718-3725. PubMed ID: 28579231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71.
    Zhang C; Yang Y; Chi Y; Yin J; Yan L; Ku Z; Liu Q; Huang Z; Zhou D
    Vaccine; 2015 Sep; 33(39):5087-94. PubMed ID: 26296491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Similar protective immunity induced by an inactivated enterovirus 71 (EV71) vaccine in neonatal rhesus macaques and children.
    Zhang Y; Wang L; Liao Y; Liu L; Ma K; Yang E; Wang J; Che Y; Jiang L; Pu J; Guo L; Feng M; Liang Y; Cui W; Yang H; Li Q
    Vaccine; 2015 Nov; 33(46):6290-7. PubMed ID: 26419198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection.
    Bek EJ; Hussain KM; Phuektes P; Kok CC; Gao Q; Cai F; Gao Z; McMinn PC
    Vaccine; 2011 Jun; 29(29-30):4829-38. PubMed ID: 21550375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases.
    Liu CC; Chow YH; Chong P; Klein M
    Vaccine; 2014 Oct; 32(47):6177-82. PubMed ID: 25218294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative study of multiple clinical enterovirus 71 isolates and evaluation of cross protection of inactivated vaccine strain FY-23 K-B in vitro.
    Yang T; Li H; Yue L; Song X; Xie T; Ma S; Meng H; Zhang Y; He X; Long R; Yang R; Luo F; Xie Z; Li Q
    Virol J; 2017 Oct; 14(1):206. PubMed ID: 29073897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine.
    Hankaniemi MM; Stone VM; Sioofy-Khojine AB; Heinimäki S; Marjomäki V; Hyöty H; Blazevic V; Laitinen OH; Flodström-Tullberg M; Hytönen VP
    Vaccine; 2019 Sep; 37(40):5962-5971. PubMed ID: 31471148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.